Market cap
$34.3m
End-of-day close multiplied by current shares on issue.
Full-year Cromwell consolidation and a sharp H2 earnings swing lift reported NPAT while net debt/EBITDAF falls from 11.1x to 5.8x.
Revenue context before the current result.
EBITDAF margin across covered periods.
Operating cash flow across covered periods.
Operating working-capital absorption or release by reporting period.
Market context
A close-dated read on what the market price implies next to the latest verified filing inputs. Unavailable metrics stay visible when the absence is useful context.
The latest close and share count context for the market price.
Market cap
$34.3m
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
2.66x
Recent market cap compared with trailing earnings.
EPS
0.24
Recent filing-derived earnings per share.
PEG
0.03x
P/E compared with recent earnings growth.
EV/EBITDA
11.01x
Enterprise value compared with recent EBITDA.
P/FCF
Not available
Not meaningful when free cash flow is negative or unavailable.
P/B
0.62x
Market value compared with latest reported equity.
Yield and fund-style valuation where the company shape supports it.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Key metrics
FY26 vs FY25
Revenue
$40.1m
+29.1% ↑ vs $31.1m
Net profit after tax
$12.9m
+89.7% ↑ vs $6.8m
Net cash inflow from operating activities
$6.4m
+86.9% ↑ vs $3.4m
Full-year dividend per share
0.0c
— vs —
Profit before tax
$13.9m
+107.5% ↑ vs $6.7m
Cash and cash equivalents
$0.11m
-16.7% ↓ vs $0.13m
Total assets
$199.5m
+15.9% ↑ vs $172.1m
What changed
These headline movements are not a like-for-like read: the comparative included a part-period Cromwell contribution and a discontinued Eileen Mary operation, so the year-on-year growth rates carry a basis discontinuity. The cleaner operating anchor is underlying EBITDAF of $6.6m, which the company reconciles to $4.2m in the prior year. Operating cash flow rose to $6.4m from $3.4m, while gross borrowings fell to $38.6m from $46.7m and net debt to EBITDAF moved from 11.1x to 5.8x. A dividend policy was introduced but no FY26 dividend was declared.
What matters
The HY26 release reported H1 NPAT of -$0.0m, so essentially the entire reported full-year NPAT of $12.9m landed in H2 on H2 revenue of around $20.9m. This means investors should treat the PBT and NPAT lines as containing material non-operating items and use EBITDAF as the durable earnings reference.
Net debt fell by roughly $8m and net debt/EBITDAF improved from 11.1x to 5.8x. Leverage remains elevated for an aged-care operator, but the trajectory expands capacity for the acquisition activity flagged in the HY26 release.
Management set a dividend policy but declared no FY26 distribution. Operating free cash flow remained slightly negative at -$0.2m (per the company's OFCF reconciliation), and cash on balance sheet is $0.1m, so near-term distributable capacity is constrained even as the policy signals capital-return intent.
Expectations
The release describes Cromwell as now embedded and Nelson Street as effectively full, and the HY26 release referenced early-stage acquisition negotiations. The result supports the operational repositioning narrative at the EBITDAF level, but with H2 carrying virtually all reported earnings and a basis change from the acquisition and disposal, the forward run-rate cannot be cleanly inferred from the headline. Investors should weight EBITDAF rather than NPAT when projecting forward, and watch HY27 for confirmation that the H2 EBITDAF pace (roughly $4.1m on the implied split) reflects an underlying base rather than seasonal occupancy strength.
Quality of result
Net cash from operations of $6.4m sits close to this number, so cash conversion at the EBITDAF level looks reasonable. Operating free cash flow improved to -$0.2m from -$1.3m, indicating that after capex of $0.5m, interest, and lease costs the business is roughly at cash breakeven - an improvement, but not yet a source of distributable surplus.
The less durable component is the gap between EBITDAF and reported PBT/NPAT. The H2 swing from a near-breakeven H1 to roughly $13.0m of H2 NPAT cannot be reconciled to EBITDAF and is consistent with property revaluation or other below-the-line gains typical for aged-care operators, though the source material provided does not separately disclose the driver. The effective tax rate of 7.3% (prior: 1.6%) is consistent with non-taxable or low-tax gains in that line, which reinforces the view that the NPAT growth is not a clean operating signal. The basis discontinuity from a full-year Cromwell consolidation against a part-period prior also affects revenue and earnings growth comparability.
Unresolved
This briefing cannot assess the specific composition of the $7.3m gap between EBITDAF and PBT because the source material does not separately disclose revaluation, fair-value, or other non-operating items.
Chat
Ask follow-up questions about Promisia Healthcare's FY26 result.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Open to load analytical metrics.
Open to load key metrics.
PHL FY26 NZX Results Announcement
FY26 / results announcementPHL FY26 Preliminary Financial Statements
FY26 / financial reportPHL FY26 Results Announcement
FY26 / results releasePHL FY26 Results Presentation
FY26 / results presentationPHL 2025 Annual Report
FY25 / financial reportPHL HY26 Preliminary Financial Statements
HY26 / financial reportPHL HY26 Results Announcement
HY26 / results releasePHL HY26 NZX Results Announcement
HY26 / results announcementFY26 Earnings Guidance Upgrade
FY26 / commentaryPresentation - ASM 2025
HY26 / commentaryRelated insights
Cross-company views selected from the metrics in this briefing.
Earnings quality and statutory distortions
PBT and NPAT growth diverged by 17.8pp, with a distortion flag in the result.
Leverage and balance-sheet risk
Net debt / EBITDA is 5.82x, -5.28x versus the prior comparable period.
Revenue growth context
Revenue growth was 29.1% for this reporting period.
Cash conversion quality
This result converted 96.2% of EBITDA to operating cash flow, +15.0pp versus the prior comparable period.
Get the next Promisia Healthcare briefing and related NZX reporting-season updates by email.